<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="rrm2b-mtddepl" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">rrm2b-mtddepl</book-part-id>
      <title-group>
        <title><italic toggle="yes">RRM2B</italic>-Related Mitochondrial Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gorman</surname>
            <given-names>Gr&#x000e1;inne S</given-names>
          </name>
          <degrees>MD, MRCP</degrees>
          <aff>Wellcome Trust Centre for Mitochondrial Research<break/>Newcastle University<break/>Newcastle upon Tyne, United Kingdom</aff>
          <email>grainne.gorman@newcastle.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Taylor</surname>
            <given-names>Robert W</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Wellcome Trust Centre for Mitochondrial Research<break/>Newcastle University<break/>Newcastle upon Tyne, United Kingdom</aff>
          <email>robert.taylor@newcastle.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>17</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="rob" document-type="chapter">
<italic toggle="yes">ROR2</italic>-Related Robinow Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="refsum" document-type="chapter">Refsum Disease</related-object>
      <abstract id="rrm2b-mtddepl.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">RRM2B</italic>-related mitochondrial disease can be grouped by disease pathogenesis, phenotype, and mode of inheritance into two major types: mitochondrial DNA (mtDNA) depletion and multiple mtDNA deletions.</p>
          <list list-type="bullet">
            <list-item>
              <p>Mitochondrial DNA depletion usually manifests as severe multisystem disease (encephalomyopathy with proximal renal tubulopathy) and is often fatal in early life. Inheritance is autosomal recessive.</p>
            </list-item>
            <list-item>
              <p>Multiple mtDNA deletions cause tissue-specific cytochrome <italic toggle="yes">c</italic> oxidase (COX) deficiency. Inheritance can be either autosomal recessive (with progressive external ophthalmoplegia [PEO] and multisystem involvement manifesting during early childhood/adulthood) or autosomal dominant (with less severe, often tissue-specific manifestations [e.g., chronic PEO] developing in later adulthood).</p>
            </list-item>
          </list>
          <p>Other rarer phenotypes are Kearns-Sayre syndrome (KSS) and mitochondrial neurogastrointestinal encephalopathy (MNGIE).</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The presence of biallelic <italic toggle="yes">RRM2B</italic> pathogenic variants confirms the diagnosis of an autosomal recessive <italic toggle="yes">RRM2B</italic>-related mitochondrial disease. The presence of a heterozygous <italic toggle="yes">RRM2B</italic> pathogenic variant confirms the diagnosis of an autosomal dominant <italic toggle="yes">RRM2B</italic>-related mitochondrial disease in those suspected of having a late-onset disorder of mtDNA maintenance.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> No cures and few effective treatments exist for any form of mitochondrial disease, including this one. Treatment, which focuses on symptomatic management and supportive care, is best provided by a multidisciplinary team. Management issues for those with systemic involvement may include: nutritional support (gastrointestinal involvement), care by a pediatric nephrologist (renal tubulopathy), care by a pediatric pulmonologist (impaired respiratory function), physical therapy (to maintain strength and mobility and to prevent contractures), care by a pediatric neurologist (seizures), and care by hearing loss specialists (to determine the best habilitation options for sensorineural hearing loss). Management issues for those with PEO may include: ptosis surgery for cosmetic effect and/or symptomatic relief; ECG to screen for significant cardiac conduction defects. For both clinical presentations: aggressive management of fever and infection.</p>
          <p><italic toggle="yes">Surveillance:</italic> No clinical guidelines specific to <italic toggle="yes">RRM2B</italic>-related mitochondrial disease are available; however, for those with systemic involvement the following should be considered: regular evaluation of: neurodevelopment, speech, and language; presence/severity of encephalopathy and/or seizures/subclinical status epilepticus; renal function; nutritional status, growth, and body mass index (BMI); and pulmonary function. For those with PEO the following biannual evaluations should be considered: neurologic status; occupational and physical therapy assessments; CBC, electrolytes, liver function (albumin, coagulation factors), liver enzymes (AST, ALT, GGT), blood glucose, and HBA1C; and nutritional status, weight, and body mass index (BMI).</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Specifically: Valproic acid (theoretic risk of precipitating/exacerbating organ failure due to mitochondrial toxicity); metformin (theoretic risk of exacerbating metabolic acidosis); prolonged use of linezolid (reported association with optic and peripheral neuropathy and lactic acidosis due to mitochondrial toxicity); and zidovudine (reported risk of inducing mitochondrial disease by interfering with mtDNA replication). In general: dehydration and prolonged fasting to prevent clinical deterioration.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the pathogenic variant(s) have been identified in an affected family member, it is appropriate to clarify the genetic status of at-risk relatives so that those who harbor the pathogenic variant(s) can (1) undergo timely routine surveillance for disease complications and (2) avoid possible precipitating factors.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">RRM2B</italic>-related mitochondrial disease can be inherited in either an autosomal recessive (AR) or an autosomal dominant (AD) manner.</p>
          <list list-type="bullet">
            <list-item>
              <p>AR inheritance. The parents of an affected child are obligate heterozygotes (carriers) and are asymptomatic. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>AD inheritance. Most affected individuals likely have an affected parent; the proportion caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown. The offspring of an affected individual has a 50% chance of inheriting the pathogenic variant and, thus, being symptomatic.</p>
            </list-item>
          </list>
          <p>If the pathogenic variant(s) have been identified in an affected family member, prenatal testing for pregnancies at increased risk is possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="rrm2b-mtddepl.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="rrm2b-mtddepl.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_rrm2b-mtddepl.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">RRM2B</italic>-Related Mitochondrial Disease: Included Phenotypes&#x000a0;<sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Mitochondrial DNA depletion syndrome (encephalomyopathic form with renal tubulopathy)</p></list-item><list-item><p>Mitochondrial neurogastrointestinal encephalopathy</p></list-item><list-item><p>Chronic progressive external ophthalmoplegia with multiple mtDNA deletions</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="rrm2b-mtddepl.TF.c.1">
              <label>1. </label>
              <p>For other genetic causes of these phenotypes see <xref ref-type="sec" rid="rrm2b-mtddepl.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="rrm2b-mtddepl.Diagnosis">
        <title>Diagnosis</title>
        <p><italic toggle="yes">RRM2B</italic>-related mitochondrial disease can, for the most part, be characterized by disease pathogenesis, phenotype, and mode of inheritance:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mitochondrial DNA (mtDNA) depletion, which usually manifests as severe multisystem disease (encephalomyopathy with proximal renal tubulopathy) and is often fatal in early life. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.achamroschitz.2009.300">Acham-Roschitz et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.kollberg.2009.147">Kollberg et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.shaibani.2009.1028">Shaibani et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>]</p>
          </list-item>
          <list-item>
            <p>Accumulation of clonally expanded (multiple) mtDNA deletions causing tissue-specific cytochrome <italic toggle="yes">c</italic> oxidase (COX) deficiency. Inheritance can be autosomal recessive (<bold>AR</bold>) or autosomal dominant (<bold>AD</bold>) [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.takata.2011.r92">Takata et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>AR.</bold> Disease generally manifests during early childhood/adulthood with marked multisystem involvement (chronic progressive external ophthalmoplegia [PEO] and KSS).</p>
              </list-item>
              <list-item>
                <p><bold>AD.</bold> Disease typically develops in later adulthood, is usually less severe, and is often tissue-specific, such as chronic PEO.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold><italic toggle="yes">RRM2B</italic>-related mitochondrial disease should be suspected</bold>
<bold>in the following</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Children with:</p>
            <list list-type="bullet">
              <list-item>
                <p>Myopathy manifesting as muscle hypotonia and weakness, often associated with respiratory insufficiency</p>
              </list-item>
              <list-item>
                <p>Gastrointestinal disturbance manifesting as dysmotility</p>
              </list-item>
              <list-item>
                <p>Proximal renal tubulopathy with nephrocalcinosis</p>
              </list-item>
              <list-item>
                <p>CNS findings including seizures, global developmental delay, microcephaly, and hearing loss</p>
              </list-item>
              <list-item>
                <p>Lactic acidosis</p>
              </list-item>
              <list-item>
                <p>Skeletal muscle tissue showing severe mtDNA depletion and mitochondrial respiratory chain defects</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Adults with:</p>
            <list list-type="bullet">
              <list-item>
                <p>Progressive external ophthalmoplegia (PEO)</p>
              </list-item>
              <list-item>
                <p>Ptosis of variable severity</p>
              </list-item>
              <list-item>
                <p>Proximal muscle weakness and/or fatigue</p>
              </list-item>
              <list-item>
                <p>Bulbar dysfunction</p>
              </list-item>
              <list-item>
                <p>Absent or minimal CNS findings, including ataxia, cognitive dysfunction, and mood disturbance</p>
              </list-item>
              <list-item>
                <p>Sensorineural hearing loss (SNHL)</p>
              </list-item>
              <list-item>
                <p>Sensory axonal peripheral neuropathy</p>
              </list-item>
              <list-item>
                <p>Gastrointestinal problems, including irritable bowel syndrome-like symptoms and low body mass index (BMI)</p>
              </list-item>
              <list-item>
                <p>Endocrinopathy (including hypothyroidism, hypoparathyroidism, diabetes mellitus, and hypogonadism)</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Individuals with</bold>
<related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter"><bold>Kearns-Sayre syndrome</bold></related-object> when inheritance appears to follow a Mendelian pattern and/or examination of muscle tissue reveals evidence of multiple mtDNA deletions.</p>
          </list-item>
          <list-item>
            <p><bold>Individuals with</bold>
<related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><bold>mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease</bold></related-object> when plasma thymidine concentration is &#x0003c;3 &#x000b5;mol/L, plasma deoxyuridine concentration &#x0003c;5 &#x000b5;mol/L, thymidine phosphorylase enzyme activity in leukocytes is &#x0003e;10% of the control mean, and molecular genetic testing does not identify biallelic pathogenic variants in <italic toggle="yes">TYMP</italic> (the gene encoding thymidine phosphorylase).</p>
          </list-item>
        </list>
        <p><bold>One strategy for establishing the molecular diagnosis of <italic toggle="yes">RRM2B</italic>-related mitochondrial disease in a proband</bold> is to perform a skeletal muscle biopsy to evaluate for characteristic histopathologic changes that are only apparent in muscle tissue: cytochrome <italic toggle="yes">c</italic> oxidase (COX)-deficient fibers and subsarcolemmal mitochondrial accumulation (classic &#x0201c;ragged-red&#x0201d; fibers).</p>
        <p>If the muscle tissue shows evidence of mitochondrial disease, perform (in skeletal muscle) the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Quantitative studies of mtDNA copy number for evidence of mtDNA depletion (typically &#x0003c;30% of age- and tissue-matched control samples)</p>
          </list-item>
          <list-item>
            <p>Qualitative studies for evidence of clonally expanded multiple mtDNA deletions (deletion/duplication analysis, <xref ref-type="table" rid="rrm2b-mtddepl.T.summary_of_molecular_gen">Table 1</xref>)</p>
          </list-item>
        </list>
        <p>If a skeletal muscle biopsy cannot be obtained, perform (on DNA extracted from leukocytes) sequence analysis of the entire <italic toggle="yes">RRM2B</italic> coding region, including intron/exon boundaries (<xref ref-type="table" rid="rrm2b-mtddepl.T.summary_of_molecular_gen">Table 1</xref>).</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of biallelic (i.e., compound heterozygous or homozygous) <italic toggle="yes">RRM2B</italic> pathogenic variants confirms the diagnosis of autosomal recessive <italic toggle="yes">RRM2B</italic>-related mitochondrial disease.</p>
            <p>Note: If sequence analysis does not identify biallelic <italic toggle="yes">RRM2B</italic> pathogenic variants and autosomal recessive inheritance is suspected, deletion/duplication analysis should be considered.</p>
          </list-item>
          <list-item>
            <p>The presence of a heterozygous <italic toggle="yes">RRM2B</italic> pathogenic variant confirms the diagnosis of autosomal dominant <italic toggle="yes">RRM2B</italic>-related mitochondrial disease.</p>
          </list-item>
        </list>
        <p><bold>A different strategy for establishing the molecular diagnosis of <italic toggle="yes">RRM2B</italic>-related mitochondrial disease in a proband</bold> is the use of a multi-gene panel comprising a number of genes known to disturb mtDNA maintenance (see <xref ref-type="sec" rid="rrm2b-mtddepl.Differential_Diagnosis">Differential Diagnosis</xref> for a discussion of some of these disorders).</p>
        <table-wrap id="rrm2b-mtddepl.T.summary_of_molecular_gen" orientation="portrait" position="anchor">
          <label>Table 1. </label>
          <caption>
            <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">RRM2B</italic>-Related Mitochondrial Disease</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                <th id="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                <th id="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by this Method</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <italic toggle="yes">RRM2B</italic>
                </td>
                <td headers="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_rrm2b-mtddepl.T.summary_of_molecular_gen_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>5</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="rrm2b-mtddepl.TF.1.1">
              <label>1. </label>
              <p>See <related-object source-id="gene" document-id="rrm2b-mtddepl" object-id="rrm2b-mtddepl.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="rrm2b-mtddepl.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.1.2">
              <label>2. </label>
              <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.1.3">
              <label>3. </label>
              <p>Because of the difficulty of detecting small deletions by conventional sequencing strategies, pathogenic variant frequency is reported to be &#x0003c;100%.</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.1.4">
              <label>4. </label>
              <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long <italic toggle="yes">RRM2B</italic> -range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.1.5">
              <label>5. </label>
              <p>No <italic toggle="yes">RRM2B</italic> deletions have been reported to date.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="rrm2b-mtddepl.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="rrm2b-mtddepl.Clinical_Description">
          <title>Clinical Description</title>
          <p>Pathogenic variants in <italic toggle="yes">RRM2B</italic> are associated predominantly with either:</p>
          <list list-type="bullet">
            <list-item>
              <p>Mitochondrial DNA depletion syndrome (encephalomyopathic form with renal tubulopathy), which usually presents as a childhood-onset severe multisystem disease;</p>
              <p>OR</p>
            </list-item>
            <list-item>
              <p>Chronic progressive external ophthalmoplegia with multiple mtDNA deletions, which is usually adult-onset, milder, and often tissue-specific.</p>
            </list-item>
          </list>
          <p>However, other phenotypes include <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Kearns-Sayre syndrome</related-object> and <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter">mitochondrial neurogastrointestinal encephalopathy</related-object> (MNGIE).</p>
          <p><italic toggle="yes">RRM2B</italic>-related mitochondrial diseases are emerging as an important cause of both pediatric and adult-onset mitochondrial disease. To date, 73 individuals from 42 families with molecularly confirmed <italic toggle="yes">RRM2B</italic>-related mitochondrial disease have been reported [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.achamroschitz.2009.300">Acham-Roschitz et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.kollberg.2009.147">Kollberg et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.shaibani.2009.1028">Shaibani et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.takata.2011.r92">Takata et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
          <p><bold>Mitochondrial DNA depletion syndrome (encephalomyopathic form with renal tubulopathy),</bold> the most severe form of the disease, is a multisystem disorder associated with severe mtDNA depletion; it has been reported in 15 individuals [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.achamroschitz.2009.300">Acham-Roschitz et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.kollberg.2009.147">Kollberg et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>]. Onset typically occurs in the first six months of life; affected children succumb in early childhood.</p>
          <p>Disease characteristics include myopathy manifest as muscle hypotonia (in all 15 affected individuals), weakness associated with respiratory insufficiency (in 10), lactic acidosis (13), failure to thrive and gastrointestinal dysmotility (9), and proximal renal tubulopathy with nephrocalcinosis (9) [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>].</p>
          <p>Central nervous system (CNS) features can include seizures (5 affected individuals), sensorineural hearing loss of varying severity (3), microcephaly (2), cerebral atrophy (1), and generalized central hypomyelination (1).</p>
          <p><bold>Chronic progressive external ophthalmoplegia (PEO) with multiple mtDNA deletions.</bold> In 31 adults with chronic PEO and multiple mtDNA deletions in muscle in whom mutation of all other genes known to cause this phenotype (i.e., <italic toggle="yes">POLG, POLG2, SLC25A4,</italic> and <italic toggle="yes">TWNK</italic>) had been excluded, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al [2012]</xref>, identified an autosomal dominant <italic toggle="yes">RRM2B</italic>-related disorder in 24 individuals and an autosomal recessive <italic toggle="yes">RRM2B</italic>- related disorder in seven.</p>
          <p>Ptosis and PEO were universal. Extra-ocular neurologic complications were common in adults with genetically confirmed <italic toggle="yes">RRM2B</italic>-related mitochondrial disease. Also prominent were myopathy (followed by bulbar dysfunction) and fatigue. Sensorineural hearing loss of varying severity and gastrointestinal dysmotility (including irritable bowel syndrome-like symptoms and low body mass index) were also common. Endocrinopathies including diabetes mellitus, hypothyroidism, hypoparathyroidism, and hypogonadism were important additional clinical features.</p>
          <list list-type="bullet">
            <list-item>
              <p>Autosomal dominant inheritance</p>
              <list list-type="bullet">
                <list-item>
                  <p>The first individuals reported were from two large, unrelated families with autosomal dominant PEO caused by a heterozygous nonsense pathogenic variant in exon 9 (<xref ref-type="table" rid="rrm2b-mtddepl.T.selected_rrm2b_pathogeni">c.979C &#x0003e;T</xref>) predicting p.Arg327Ter) that resulted in truncation of the translated p53R2 (see <xref ref-type="sec" rid="rrm2b-mtddepl.Molecular_Genetics">Molecular Genetics</xref>, <bold>Normal gene product</bold>) protein [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>]. In these families the earliest onset was in the third decade (average age 46 years). The cardinal features were PEO and ptosis as well as ataxia, cognitive dysfunction, exercise intolerance, sensorineural hearing loss, mood disturbance, and peripheral neuropathy.</p>
                </list-item>
                <list-item>
                  <p>More recently, heterozygous <italic toggle="yes">RRM2B</italic> pathogenic variants have been shown to be frequent in familial PEO with muscle-restricted multiple mtDNA deletions [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>]. The phenotype is a milder myopathy with proximal muscle weakness, bulbar dysfunction, and fatigue. Mean age of disease onset is 46 years.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Autosomal recessive inheritance</p>
              <list list-type="bullet">
                <list-item>
                  <p>In children with compound heterozygous <italic toggle="yes">RRM2B</italic> pathogenic variants, disease onset was at a mean age of seven years. The predominantly myopathic phenotype of PEO, ptosis, proximal muscle weakness, and bulbar dysfunction was more severe than the multisystem disorder observed in individuals with a heterozygous <italic toggle="yes">RRM2B</italic> pathogenic variant [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
                </list-item>
                <list-item>
                  <p>Additionally, a homozygous missense pathogenic variant in <italic toggle="yes">RRM2B</italic> has been described in a 43-year-old man who presented at age 16 years with progressive hearing loss followed by the insidious onset of PEO, muscle weakness, retinopathy, and a major depressive disorder, findings that further extend the phenotype [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.takata.2011.r92">Takata et al 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><bold>Mitochondrial neurogastrointestinal encephalopathy</bold></related-object>
<bold>(MNGIE)</bold> has been reported in a woman age 42 years with <italic toggle="yes">RRM2B</italic> biallelic missense pathogenic variants and mtDNA depletion in clinically relevant tissues [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.shaibani.2009.1028">Shaibani et al 2009</xref>]. For more information about this phenotype, see <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter">MNGIE</related-object>.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter"><bold>Kearns-Sayre syndrome</bold></related-object>
<bold>(KSS).</bold>
<italic toggle="yes">RRM2B</italic> pathogenic variants have been identified in one individual with onset before age 20 years of PEO-plus / Kearns-Sayre syndrome (PEO, pigmentary retinopathy, sensorineural hearing loss, and increased CSF protein), which is similar to single mtDNA deletion disorders [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>].</p>
        </sec>
        <sec id="rrm2b-mtddepl.GenotypePhenotype_Correlat">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations cannot be clearly defined in <italic toggle="yes">RRM2B</italic>-related mitochondrial disease. <italic toggle="yes">RRM2B</italic> pathogenic variants have been associated with both simplex (i.e., a single occurrence in a family) and familial mitochondrial disease characterized by either autosomal recessive mtDNA depletion syndrome (which is associated with a quantitative loss of mtDNA copies) or autosomal recessive and autosomal dominant pathogenic variants (which cause the accumulation of multiple mtDNA deletions in post-mitotic tissues).</p>
          <p>The same <italic toggle="yes">RRM2B</italic> pathogenic variants are associated with varied phenotypic severity depending on whether they are biallelic or heterozygous.</p>
          <p>Mitochondrial DNA depletion is commonly seen in children with clinically severe biallelic pathogenic variants in genes encoding proteins essential to mtDNA maintenance [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.achamroschitz.2009.300">Acham-Roschitz et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.kollberg.2009.147">Kollberg et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.shaibani.2009.1028">Shaibani et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>]; however, it has also been observed in one adult with biallelic <italic toggle="yes">RRM2B</italic> pathogenic variants [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.shaibani.2009.1028">Shaibani et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.takata.2011.r92">Takata et al 2011</xref>]. Thus, <italic toggle="yes">RRM2B</italic>-related mtDNA depletion can potentially cause a relatively mild clinical phenotype.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Penetrance">
          <title>Penetrance</title>
          <p>The clinical manifestations of <italic toggle="yes">RRM2B</italic>-related disorders are similar in males and females.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of <italic toggle="yes">RRM2B-</italic>related mitochondrial disorders is unknown.</p>
          <p>Pathogenic variants in <italic toggle="yes">RRM2B</italic> are now increasingly recognized as an important cause of familial mitochondrial disease in both adults and children and represent the third most common cause of multiple mtDNA deletions in adults, following pathogenic variants in <italic toggle="yes">POLG</italic> (encoding pol &#x003b3;) and <italic toggle="yes">TWNK</italic> (encoding the Twinkle helicase) [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="rrm2b-mtddepl.Genetically_Related_Alleli">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">RRM2B</italic>.</p>
      </sec>
      <sec id="rrm2b-mtddepl.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The first reported human diseases attributed to mutation of <italic toggle="yes">RRM2B</italic> were associated with a quantitative loss of mtDNA copies &#x02013; the so-called mtDNA depletion syndromes. To date, mutation of the following nine nuclear genes has been associated with mtDNA depletion syndromes: <italic toggle="yes">DGUOK, MPV17, TWNK, POLG, SUCLA2, SUCLG1, TK2, TYMP,</italic> and <italic toggle="yes">RRM2B.</italic> Clinical characteristics (and the associated gene) can be summarized as [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.suomalainen.2010.429">Suomalainen &#x00026; Isohanni 2010</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myopathic (<related-object link-type="booklink" source-id="gene" document-id="tk2-mtddepl" document-type="chapter"><italic toggle="yes">TK2</italic></related-object>)</p>
          </list-item>
          <list-item>
            <p>Hepatocerebral (<related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter"><italic toggle="yes">DGUOK</italic></related-object>, <related-object link-type="booklink" source-id="gene" document-id="mpv17-mtdep" document-type="chapter"><italic toggle="yes">MPV17</italic></related-object>, <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic></related-object>, and <italic toggle="yes">TWNK</italic>)</p>
          </list-item>
          <list-item>
            <p>Encephalomyopathic (<related-object link-type="booklink" source-id="gene" document-id="sucla2-def" document-type="chapter"><italic toggle="yes">SUCLA2</italic></related-object>, <related-object link-type="booklink" source-id="gene" document-id="suclg1-mtddepl" document-type="chapter"><italic toggle="yes">SUCLG1</italic></related-object>, <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><italic toggle="yes">TYMP</italic></related-object>, and <italic toggle="yes">RRM2B</italic>)</p>
          </list-item>
        </list>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS603041">Mitochondrial DNA depletion syndrome: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
        <p>
          <bold>Comparison of <italic toggle="yes">RRM2B-</italic>related mitochondrial disorders with other mtDNA depletion and mtDNA deletion syndromes</bold>
        </p>
        <p><bold>In children.</bold> Hypotonia, lactic acidosis, and proximal renal tubulopathy in association with mitochondrial respiratory chain defects and severe mtDNA depletion in skeletal muscle should prompt testing of <italic toggle="yes">RRM2B</italic> before other nuclear-encoded genes (in which muscle weakness is the predominant clinical feature). In children with biallelic <italic toggle="yes">RRM2B</italic> pathogenic variants gastrointestinal disturbance is often severe, but CNS involvement is less common than in other syndromic mitochondrial disorders [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
        <p><bold>In adults.</bold> Progressive external ophthalmoplegia (PEO)<italic toggle="yes">,</italic> ptosis, and proximal muscle weakness are the predominant clinical characteristics seen with mutation of <italic toggle="yes">POLG</italic> and <italic toggle="yes">TWNK</italic> (encoding twinkle), the two most common causes of multiple mtDNA deletions. In contrast, bulbar dysfunction, sensorineural hearing loss, and gastrointestinal problems (including irritable bowel syndrome-like symptoms and low body mass index) appear to occur more often in adults with mutation of <italic toggle="yes">RRM2B</italic> than mutation of <italic toggle="yes">POLG</italic> or <italic toggle="yes">TWNK</italic>. Thus, in adults the presence of PEO<italic toggle="yes">,</italic> multiple mtDNA deletions in skeletal muscle, bulbar dysfunction, sensorineural hearing loss, and gastrointestinal problems in the absence of overt CNS features supports testing of <italic toggle="yes">RRM2B</italic> before <italic toggle="yes">POLG</italic> and <italic toggle="yes">TWNK</italic>.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter"><bold>Kearns-Sayre syndrome</bold></related-object>
<bold>(KSS).</bold>
<italic toggle="yes">RRM2B</italic> testing should be considered when the pattern of inheritance appears to be Mendelian and/or evidence of multiple mtDNA deletions is observed on muscle biopsy.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><bold>Mitochondrial neurogastrointestinal encephalopathy</bold></related-object>
<bold>(MNGIE).</bold>
<italic toggle="yes">RRM2B</italic> testing should be considered in individuals with MNGIE if deoxyuridine and thymidine levels in both blood and urine are negative, thymidine phosphorylase activity is normal in white cells and platelets, and molecular genetic testing does not identify causative pathogenic variants in <italic toggle="yes">TYMP</italic>.</p>
      </sec>
      <sec id="rrm2b-mtddepl.Management">
        <title>Management</title>
        <sec id="rrm2b-mtddepl.Evaluations_Following_Init">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">RRM2B</italic>-related mitochondrial disease, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Comprehensive clinical examination and neurology consultation that includes measures of functional neurologic status</p>
            </list-item>
            <list-item>
              <p>Formal developmental evaluation (particularly in a child with the encephalomyopathic form with renal tubulopathy)</p>
            </list-item>
            <list-item>
              <p>Formal assessment of vision and hearing</p>
            </list-item>
            <list-item>
              <p>Brain MRI and electroencephalogram (EEG) in individuals with encephalopathy and/or seizures. Note: these may be normal with certain <italic toggle="yes">RRM2B</italic>-related mitochondrial disease phenotypes.</p>
            </list-item>
            <list-item>
              <p>Nutritional assessment</p>
            </list-item>
            <list-item>
              <p>Speech and language assessment</p>
            </list-item>
            <list-item>
              <p>Physical therapy assessment</p>
            </list-item>
            <list-item>
              <p>Occupational therapy assessment</p>
            </list-item>
            <list-item>
              <p>Pulmonary function testing</p>
            </list-item>
            <list-item>
              <p>For those with Kearns-Sayre syndrome, cardiac evaluation to include electrocardiogram (ECG) and/or echocardiogram</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="rrm2b-mtddepl.Treatment_of_Manifestation">
          <title>Treatment of Manifestations</title>
          <p>Detailed evaluations are outlined in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.newcastle-mitochondria.com/clinical-professional-home-page/clinical-publications/clinical-guidelines/">Wellcome Trust Centre for Mitochondrial Research Clinical Guidelines</ext-link>.</p>
          <p>To date, there are no known cures and few effective treatments for any forms of mitochondrial disease, including <italic toggle="yes">RRM2B</italic>-related mitochondrial disease. Treatment modalities currently focus on symptomatic management and supportive care, and are best implemented by a multidisciplinary team.</p>
          <p>General management guidelines for those with systemic involvement:</p>
          <list list-type="bullet">
            <list-item>
              <p>Nutritional support (e.g., nasogastric tube, gastrostomy) as needed for significant gastrointestinal involvement</p>
            </list-item>
            <list-item>
              <p>Early referral to a pediatric renal specialist for those with proximal renal tubulopathy</p>
            </list-item>
            <list-item>
              <p>Early referral to a pediatric pulmonologist for children with evidence of reduced respiratory function. Management may include consideration of tracheostomy and artificial ventilation.</p>
            </list-item>
            <list-item>
              <p>Physical therapy to maintain muscle strength and mobility and to prevent contractures</p>
            </list-item>
            <list-item>
              <p>Referral to a pediatric neurologist for seizure management. Of note, seizures may be refractory to treatment.</p>
            </list-item>
            <list-item>
              <p>Referral to hearing loss specialists to determine the best habilitation options for sensorineural hearing loss (see <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Hearing Loss and Deafness</related-object> for discussion of management issues)</p>
            </list-item>
          </list>
          <p>General management guidelines for those with progressive external ophthalmoplegia (PEO):</p>
          <list list-type="bullet">
            <list-item>
              <p>Ptosis surgery for cosmesis and/or symptomatic relief in those with good residual orbicularis oculi muscle strength</p>
            </list-item>
            <list-item>
              <p>ECG in all individuals with PEO to screen for significant cardiac conduction defects which may warrant placement of a pacemaker, particularly in those with the <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Kearns-Sayre syndrome</related-object> phenotype</p>
            </list-item>
          </list>
          <p>General management guidelines for both those with systemic involvement and those with PEO:</p>
          <list list-type="bullet">
            <list-item>
              <p>Aggressive management of fever and infection</p>
            </list-item>
          </list>
        </sec>
        <sec id="rrm2b-mtddepl.Surveillance">
          <title>Surveillance</title>
          <p>No clinical guidelines specific to <italic toggle="yes">RRM2B</italic>-related mitochondrial disease are available; however, detailed evaluations are outlined in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.newcastle-mitochondria.com/clinical-professional-home-page/clinical-publications/clinical-guidelines/">Wellcome Trust Centre for Mitochondrial Research Clinical Guidelines</ext-link>.</p>
          <p>The following evaluations should be considered:</p>
          <p>
            <bold><italic toggle="yes">RRM2B</italic>-related mitochondrial DNA depletion syndrome (encephalo-myopathic form with renal tubulopathy)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Regular assessments of neurodevelopment, speech, and language</p>
            </list-item>
            <list-item>
              <p>Regular evaluations by a pediatric neurologist to evaluate for the presence and/or severity of encephalopathy, with consideration of EEG and video EEG monitoring to determine presence of seizures and/or subclinical status epilepticus</p>
            </list-item>
            <list-item>
              <p>Regular evaluation by a pediatric renal specialist, including assessment of renal function (electrolytes in blood and urine and urine analysis)</p>
            </list-item>
            <list-item>
              <p>Routine assessment of nutritional status, growth, and body mass index (BMI)</p>
            </list-item>
            <list-item>
              <p>Regular pulmonary function testing including monitoring of blood gases for early detection of respiratory compromise</p>
            </list-item>
          </list>
          <p>
            <bold><italic toggle="yes">RRM2B</italic>-related mitochondrial DNA depletion syndrome and mitochondrial neurogastrointestinal encephalopathy</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Biannual:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Comprehensive neurology consultation and clinical examination to include measures of functional neurologic status</p>
                </list-item>
                <list-item>
                  <p>Occupational therapy and physical therapy assessments</p>
                </list-item>
                <list-item>
                  <p>CBC, electrolytes, liver function (albumin, coagulation factors), liver enzymes (AST, ALT, GGT), blood glucose, and HBA1C</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Annual pulmonary function testing including assessment of blood gases to monitor for early respiratory compromise</p>
            </list-item>
            <list-item>
              <p>Routine assessment of nutritional status, weight gain, and BMI, including regular review with speech and language therapist with consideration of gastrostomy as needed for nutritional support</p>
            </list-item>
            <list-item>
              <p>Imaging and diagnostic procedures including EEG, ECG, and brain MRI as indicated by clinical findings and rate of disease progression</p>
            </list-item>
          </list>
          <p>
            <bold><italic toggle="yes">RRM2B</italic>-related multiple mtDNA deletions with external ophthalmoplegia</bold>
          </p>
          <p>Care will be directed by clinical findings. The following general evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Biannual:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Comprehensive neurology consultation and clinical examination to include measures of functional neurologic status</p>
                </list-item>
                <list-item>
                  <p>Occupational therapy and physical therapy assessments</p>
                </list-item>
                <list-item>
                  <p>CBC, electrolytes, liver function (albumin, coagulation factors), liver enzymes (AST, ALT, GGT), blood glucose, and HBA1C</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Annual pulmonary function testing including assessment of blood gases to monitor for early respiratory compromise</p>
            </list-item>
            <list-item>
              <p>Routine assessment of nutritional status, weight gain and BMI, biannually</p>
            </list-item>
            <list-item>
              <p>Imaging and diagnostic procedures to include EEG, ECG, and MRI brain- as indicated by clinical findings and rate of disease progression</p>
            </list-item>
            <list-item>
              <p>ECG advised biannually (KSS phenotype)</p>
            </list-item>
          </list>
        </sec>
        <sec id="rrm2b-mtddepl.AgentsCircumstances_to_Avo">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Valproic acid (commonly used for seizures and known to interfere with beta-oxidation) because it is considered to be a mitochondrial toxin with a theoretic risk of precipitating/exacerbating organ failure</p>
            </list-item>
            <list-item>
              <p>Metformin (used to treat diabetes mellitus) because of the theoretic risk of exacerbating metabolic acidosis</p>
            </list-item>
            <list-item>
              <p>Prolonged use of linezolid (an antibiotic used to treat <italic toggle="yes">S. aureus</italic> infections) because of the reported association with optic and peripheral neuropathy and lactic acidosis due to mitochondrial toxicity</p>
            </list-item>
            <list-item>
              <p>Zidovudine (an antiretroviral nucleoside analog reverse transcriptase used to treat HIV) because of the reported risk of inducing mitochondrial disease by interfering with mtDNA replication</p>
            </list-item>
            <list-item>
              <p>Dehydration and prolonged fasting, which can lead to clinical deterioration</p>
            </list-item>
          </list>
        </sec>
        <sec id="rrm2b-mtddepl.Evaluation_of_Relatives_at">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the pathogenic variant(s) have been identified in an affected family member, it is appropriate to clarify the genetic status of at-risk relatives so that those who harbor the pathogenic variant(s) can (1) undergo timely routine <xref ref-type="sec" rid="rrm2b-mtddepl.Surveillance">surveillance</xref> for disease complications and (2) <xref ref-type="sec" rid="rrm2b-mtddepl.AgentsCircumstances_to_Avo">avoid possible precipitating factors</xref>.</p>
          <p>See <xref ref-type="sec" rid="rrm2b-mtddepl.Related_Genetic_Counseling">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Therapies_Under_Investigat">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="rrm2b-mtddepl.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="rrm2b-mtddepl.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">RRM2B</italic>-related mitochondrial DNA depletion syndrome (encephalomyopathic form with renal tubulopathy) and <italic toggle="yes">RRM2B</italic>-related mitochondrial neurogastrointestinal encephalopathy are inherited in an autosomal recessive manner.</p>
          <p><italic toggle="yes">RRM2B</italic>-related chronic progressive external ophthalmoplegia with multiple mtDNA deletions can be inherited in either an autosomal dominant or autosomal recessive manner.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Risk_to_Family_Members__Au">
          <title>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with <italic toggle="yes">RRM2B</italic>-related mitochondrial DNA depletion syndrome, (encephalomyopathic form with renal tubulopathy) are not known to reproduce.</p>
            </list-item>
            <list-item>
              <p>The offspring of individuals with less severe manifestations of <italic toggle="yes">RRM2B</italic>-related disorders are obligate heterozygotes for an <italic toggle="yes">RRM2B</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Risk_to_Family_Members__Au_1">
          <title>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals diagnosed with autosomal dominant <italic toggle="yes">RRM2B</italic>-related chronic progressive external ophthalmoplegia with multiple mtDNA deletions likely have an affected parent; the proportion resulting from <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband in whom mutation apparently occurred <italic toggle="yes">de novo</italic> include determining the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>At conception, if a parent of the proband is affected and/or has an <italic toggle="yes">RRM2B</italic> pathogenic variant, each sib has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of individuals with an autosomal dominant <italic toggle="yes">RRM2B</italic>-related disorder have a 50% chance of inheriting the <italic toggle="yes">RRM2B</italic> pathogenic variant.</p>
          <p><bold>Other family members.</bold> The risk to other family members of a proband depends on the status of the proband&#x02019;s parents.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Related_Genetic_Counseling">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="rrm2b-mtddepl.Evaluation_of_Relatives_at">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling&#x000a0;(including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="rrm2b-mtddepl.Prenatal_Testing_and_Preim">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">RRM2B</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for <italic toggle="yes">RRM2B</italic>-related mitochondrial disease are possible.</p>
        </sec>
      </sec>
      <sec id="rrm2b-mtddepl.Resources">
        <title>Resources</title>
      </sec>
      <sec id="rrm2b-mtddepl.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">RRM2B,</italic> a nuclear-encoded mitochondrial maintenance gene, comprises nine coding exons. Alternate splicing results in multiple transcript variants (see <related-object source-id="gene" document-id="rrm2b-mtddepl" object-id="rrm2b-mtddepl.molgen.TA">Table A</related-object>). The longest known transcript variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_015713.4">NM_015713.4</ext-link> ) encodes a 351-amino acid protein (molecular weight 37 kd). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="rrm2b-mtddepl" object-id="rrm2b-mtddepl.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> To date, 73 individuals from 42 families have been reported to harbor:</p>
        <list list-type="bullet">
          <list-item>
            <p>17 different <italic toggle="yes">RRM2B</italic> pathogenic variants in mtDNA depletion syndrome [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bourdon.2007.776">Bourdon et al 2007</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.bornstein.2008.453">Bornstein et al 2008</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.achamroschitz.2009.300">Acham-Roschitz et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.kollberg.2009.147">Kollberg et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>];</p>
          </list-item>
          <list-item>
            <p>22 different <italic toggle="yes">RRM2B</italic> pathogenic variants in mtDNA deletion disorders [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.takata.2011.r92">Takata et al 2011</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
          </list-item>
        </list>
        <p>The majority of reported <italic toggle="yes">RRM2B</italic> pathogenic variants are missense variants. Spliced transcript variants have also been described [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.spinazzola.2009.143">Spinazzola et al 2009</xref>].</p>
        <p>Identification of truncating pathogenic variants in exon 9 in unrelated individuals with familial autosomal dominant PEO has shown that the mutated mRNA escapes nonsense mediated decay and results in a truncated protein that has been postulated to cause a dominant-negative or gain-of-function effect on the heterotetrameric structure of the RNR enzyme, identifying exon 9 as a mutation hot spot [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.fratter.2011.2032">Fratter et al 2011</xref>].</p>
        <table-wrap id="rrm2b-mtddepl.T.selected_rrm2b_pathogeni" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">RRM2B</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.48G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">(Glu16Glu)&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_3" rowspan="36" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_015713.4">NM_015713.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_056528.2">NP_056528.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.121C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg41Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.122G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg41Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.122G&#x0003e;C</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg41Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.190T&#x0003e;C</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp64Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.208G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp70Asn</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.253_255delGAG</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu85del</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.322-2A&#x0003e;C<break/>(IVS3-2A&#x0003e;C)</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.322-2A&#x0003e;G<break/>(IVS3-2A&#x0003e;G)</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.328C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg110Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.329G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg110His</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.97C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro33Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.362G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg121His</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.368T&#x0003e;C</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe123Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.391G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu131Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.431C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr144Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.556A&#x0003e;G</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg186Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.580G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu194Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.581A&#x0003e;G</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu194Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.583G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly195Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.584delG</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly195GlufsTer14</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.606T&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe202Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.632G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg211Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.686G&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly229Val</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.671T&#x0003e;G</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile224Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.707G&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys236Phe</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.817G&#x0003e;A</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly273Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.846G&#x0003e;C</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met282Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.850C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln284Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.920delA</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn307IlefsTer11</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.949T&#x0003e;G</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu317Val</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.950delT</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu317Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.952G&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu318Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.965dupA</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn322LysfsTer4</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.979C&#x0003e;T</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg327Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1046C&#x0003e;G</td>
                <td headers="hd_h_rrm2b-mtddepl.T.selected_rrm2b_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala349Gly</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="rrm2b-mtddepl.TF.2.2">
              <label>2. </label>
              <p>Evidence to support pathogenicity includes aberrant splicing, partial intron retention, and premature termination of translation &#x02013; predicting absence of any functional protein from this allele [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>].</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">RRM2B</italic> encodes <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uniprot.org/uniprot/Q7LG56">ribonucleoside-diphosphate reductase subunit M2 B</ext-link>, the p53-inducible small subunit (p53R2) of ribonucleotide reductase (RNR), a heterotetrameric enzyme that catalyzes <italic toggle="yes">de novo</italic> syntheses of dNTPs by direct reduction of ribonucleoside diphosphates to their corresponding deoxyribonucleoside diphosphates. This process supplements the dNTPs produced by the mitochondrial dNTP salvage pathway that is essential for mtDNA synthesis (and in which defects cause many of the mtDNA depletion syndromes [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.rahman.2009.3">Rahman &#x00026; Poulton 2009</xref>]. Transcription of <italic toggle="yes">RRM2B</italic> is tightly regulated by the tumor suppressor protein p53.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">RRM2B</italic> pathogenic variants result in disruption of mtDNA maintenance (replication and repair), leading to qualitative (accumulation of multiple mtDNA deletions) and/or quantitative (depletion of mtDNA copy number) downstream mitochondrial genomic effects.</p>
        <p>Adult-onset chronic progressive external ophthalmoplegia (CPEO)/multiple mtDNA deletion disorders are associated with autosomal recessive and autosomal dominant <italic toggle="yes">RRM2B</italic> pathogenic variants. To further understand the functional consequence of adult-onset CPEO/multiple mtDNA deletion disorders associated with both autosomal recessive and autosomal dominant <italic toggle="yes">RRM2B</italic> pathogenic variants, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al [2011]</xref> mapped the positions of the mutated amino acids on the tertiary p53R2 structure [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.smith.2009.11134">Smith et al 2009</xref>]. Many of the missense pathogenic variants identified appear likely to affect the iron-binding properties of p53R2, and hence impair the catalytic capability of the functional heterotetramer (two p53R2 subunits and two R1 subunits). Gly195, Phe202, and Ile224 are located around the iron-binding pocket. The effect of p.Phe202Leu may be orchestrated through subtle hydrophobic contacts; the effect of amino acids Gly195 and Ile224 is less subtle. Because p.Gly195Arg and p.Ile224Ser are positioned adjacent to amino acids that contribute to the iron coordination environment, substitutions at these two locations influence their amino acid neighbors and alter the coordination of the iron atom(s).</p>
        <p>Previous molecular modeling indicated that p.Arg41Gln prevents formation of a salt bridge which is important in the conformational changes that control iron binding [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.smith.2009.11134">Smith et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>]. The variant p.Arg41Trp is also predicted to prevent formation of this salt bridge. Arg211 forms a salt bridge to Glu85, which is thought to be important in stabilizing the di-iron form [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.smith.2009.11134">Smith et al 2009</xref>, <xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2011.610">Pitceathly et al 2011</xref>] and, therefore, p.Arg211Lys may also destabilize the di-iron subunit.</p>
        <p>Thr144, Arg186, Thr218, and Gly273 are all located at the end of &#x02013; or, in the case of Gly273, between &#x02013; &#x003b1;-helices and appear to stabilize the orientation of the helices. Mutation of these four amino acids may reduce protein folding efficiency and is associated with autosomal recessive disease [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.pitceathly.2012.3392">Pitceathly et al 2012</xref>].</p>
        <p>The effect of the p.Asp70Asn pathogenic variant cannot readily be predicted, as Asp70 lies in a poorly understood region of the protein between two helices.</p>
        <p>The variant p.Ala349Gly could not be modeled because the crystal structure does not include the C-terminal portion of the protein. However, Ala349 is located within a conserved heptapeptide (amino acids 345-351) required for interaction with the R1 subunit [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>], and loss of this heptapeptide has been proposed as the pathologic basis of the exon 9 truncating pathogenic variants [<xref ref-type="bibr" rid="rrm2b-mtddepl.REF.tyynismaa.2009.290">Tyynismaa et al 2009</xref>].</p>
      </sec>
      <sec id="rrm2b-mtddepl.References">
        <title>References</title>
        <sec id="rrm2b-mtddepl.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="rrm2b-mtddepl.Literature_Cited.reflist0">
            <ref id="rrm2b-mtddepl.REF.achamroschitz.2009.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Acham-Roschitz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindbichler</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bittner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mache</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2009</year>
                <volume>98</volume>
                <fpage>300</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19616983</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.bornstein.2008.453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bornstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Area</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanigan</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jayakar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swoboda</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coku</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2008</year>
                <volume>18</volume>
                <fpage>453</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18504129</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.bourdon.2007.776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourdon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minai</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jais</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chr&#x000e9;tien</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paquis-Flucklinger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arakawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.</article-title>
                <source>Nat Genet.</source>
                <year>2007</year>
                <volume>39</volume>
                <fpage>776</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">17486094</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.fratter.2011.2032">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fratter</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alston</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakely</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craig</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seller</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czermin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brierley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staunton</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnpenny</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <article-title>RRM2B mutations are frequent in familial PEO with multiple mtDNA deletions.</article-title>
                <source>Neurology.</source>
                <year>2011</year>
                <volume>76</volume>
                <fpage>2032</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21646632</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.kollberg.2009.147">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kollberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moslemi</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tulinius</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldfors</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2009</year>
                <volume>19</volume>
                <fpage>147</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">19138848</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.pitceathly.2011.610">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pitceathly</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassone</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taanman</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadowski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fratter</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mudanohwo</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodward</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holton</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Kearns-Sayre syndrome caused by defective R1/p53R2 assembly.</article-title>
                <source>J Med Genet.</source>
                <year>2011</year>
                <volume>48</volume>
                <fpage>610</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21378381</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.pitceathly.2012.3392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pitceathly</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fratter</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alston</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craig</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakely</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shabbir</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deschauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pohl</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halfpenny</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnpenny</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunt</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorman</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <article-title>Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics.</article-title>
                <source>Brain.</source>
                <year>2012</year>
                <volume>135</volume>
                <fpage>3392</fpage>
                <lpage>403</lpage>
                <pub-id pub-id-type="pmid">23107649</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.rahman.2009.3">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis of mitochondrial DNA depletion syndromes.</article-title>
                <source>Arch Dis Child.</source>
                <year>2009</year>
                <volume>94</volume>
                <fpage>3</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19103785</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.shaibani.2009.1028">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shaibani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shchelochkov</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katsonis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichtarge</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinawi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.</article-title>
                <source>Arch Neurol.</source>
                <year>2009</year>
                <volume>66</volume>
                <fpage>1028</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">19667227</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.smith.2009.11134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yen</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase .</article-title>
                <source>Biochemistry.</source>
                <year>2009</year>
                <volume>48</volume>
                <fpage>11134</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">19728742</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.spinazzola.2009.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Invernizzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meznaric-Petrusa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baruffini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and molecular features of mitochondrial DNA depletion syndromes.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2009</year>
                <volume>32</volume>
                <fpage>143</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">19125351</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.suomalainen.2010.429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isohanni</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial DNA depletion syndromes--many genes, common mechanisms.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2010</year>
                <volume>20</volume>
                <fpage>429</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">20444604</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.takata.2011.r92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshikawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanba</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Exome sequencing identifies a novel missense variant in RRM2B associated with autosomal recessive progressive external ophthalmoplegia.</article-title>
                <source>Genome Biol.</source>
                <year>2011</year>
                <volume>12</volume>
                <fpage>R92</fpage>
                <pub-id pub-id-type="pmid">21951382</pub-id>
              </element-citation>
            </ref>
            <ref id="rrm2b-mtddepl.REF.tyynismaa.2009.290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tyynismaa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ylikallio</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molnar</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haller</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2009</year>
                <volume>85</volume>
                <fpage>290</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19664747</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="rrm2b-mtddepl.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="rrm2b-mtddepl.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mitoresearch.org.uk/">
              <bold>Wellcome Trust Centre for Mitochondrial Research</bold>
            </ext-link>
          </p>
          <p>Institute for Ageing and HealthNewcastle UniversityMedical SchoolFramlington PlaceNewcastle upon TyneNE2 4HHTelephone: 0191 222 3009Fax:0191 222 5685</p>
        </sec>
        <sec id="rrm2b-mtddepl.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 April 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>31 May 2013 (gg) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
